Standards for fecal microbiota transplant: Tools and therapeutic advances

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-03-21 DOI:10.1016/j.biologicals.2024.101758

Ilia Belotserkovsky , Lisa M. Stabryla , Monique Hunter , Jessica Allegretti , Benjamin J. Callahan , Paul E. Carlson , Phillip J. Daschner , Maryam Goudarzi , Cyril Guyard , Scott A. Jackson , Krishna Rao , Stephanie L. Servetas , Harry Sokol , Jennifer A. Wargo , Shawn Novick

{"title":"Standards for fecal microbiota transplant: Tools and therapeutic advances","authors":"Ilia Belotserkovsky , Lisa M. Stabryla , Monique Hunter , Jessica Allegretti , Benjamin J. Callahan , Paul E. Carlson , Phillip J. Daschner , Maryam Goudarzi , Cyril Guyard , Scott A. Jackson , Krishna Rao , Stephanie L. Servetas , Harry Sokol , Jennifer A. Wargo , Shawn Novick","doi":"10.1016/j.biologicals.2024.101758","DOIUrl":null,"url":null,"abstract":"<div><p>Fecal microbiota transplantation (FMT) has been demonstrated to be efficacious in preventing recurrent <em>Clostridioides difficile</em> (<em>C. difficile</em>) infections, and is being investigated for treatment of several other diseases including inflammatory bowel disease, cancer, obesity, liver disease, and diabetes. To speed up the translation of FMT into clinical practice as a safe and standardized therapeutic intervention, additional evidence-based technical and regulatory guidance is needed. To this end in May of 2022, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a second webinar to discuss key issues still impeding the advancement and standardization of FMT. The goal of this two-day webinar was to provide a forum for scientific experts to share and discuss data and key challenges with one another. Discussion included a focus on the evaluation of safety, efficacy, clinical trial design, reproducibility and accuracy in obtained microbiome measurements and data reporting, and the potential for standardization across these areas. It also focused on increasing the application potential and visibility of FMT beyond treating <em>C. difficile</em> infections.</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1045105624000150","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Fecal microbiota transplantation (FMT) has been demonstrated to be efficacious in preventing recurrent Clostridioides difficile (C. difficile) infections, and is being investigated for treatment of several other diseases including inflammatory bowel disease, cancer, obesity, liver disease, and diabetes. To speed up the translation of FMT into clinical practice as a safe and standardized therapeutic intervention, additional evidence-based technical and regulatory guidance is needed. To this end in May of 2022, the International Alliance for Biological Standardization (IABS) and the BIOASTER Microbiology Technology Institute hosted a second webinar to discuss key issues still impeding the advancement and standardization of FMT. The goal of this two-day webinar was to provide a forum for scientific experts to share and discuss data and key challenges with one another. Discussion included a focus on the evaluation of safety, efficacy, clinical trial design, reproducibility and accuracy in obtained microbiome measurements and data reporting, and the potential for standardization across these areas. It also focused on increasing the application potential and visibility of FMT beyond treating C. difficile infections.

查看原文本刊更多论文

粪便微生物群移植标准：工具和治疗进展

粪便微生物菌群移植（FMT）已被证明可有效预防艰难梭菌（C. difficile）的复发性感染，目前正被研究用于治疗其他几种疾病，包括炎症性肠病、癌症、肥胖症、肝病和糖尿病。为加快将 FMT 作为一种安全、标准化的治疗干预措施应用于临床实践，需要更多基于证据的技术和监管指导。为此，国际生物标准化联盟（IABS）和 BIOASTER 微生物技术研究所于 2022 年 5 月举办了第二次网络研讨会，讨论仍在阻碍 FMT 发展和标准化的关键问题。为期两天的网络研讨会旨在为科学专家提供一个论坛，相互交流和讨论数据及关键挑战。讨论的重点包括安全性评估、疗效、临床试验设计、微生物组测量和数据报告的可重复性和准确性，以及在这些领域实现标准化的可能性。会议还重点讨论了如何提高 FMT 在治疗艰难梭菌感染之外的应用潜力和知名度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.